ES2986461T3 - Método para producir un compuesto ópticamente activo - Google Patents

Método para producir un compuesto ópticamente activo Download PDF

Info

Publication number
ES2986461T3
ES2986461T3 ES18808978T ES18808978T ES2986461T3 ES 2986461 T3 ES2986461 T3 ES 2986461T3 ES 18808978 T ES18808978 T ES 18808978T ES 18808978 T ES18808978 T ES 18808978T ES 2986461 T3 ES2986461 T3 ES 2986461T3
Authority
ES
Spain
Prior art keywords
group
optionally substituted
salt
acid
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18808978T
Other languages
English (en)
Spanish (es)
Inventor
Sayuri Hirano
Yoshiyuki Takeda
Koji Nakamoto
Motoki Ikeuchi
Masato Kitayama
Masatoshi Yamada
Jun-Ichi Kawakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Day One Biopharmaceuticals Inc
Original Assignee
Day One Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Day One Biopharmaceuticals Inc filed Critical Day One Biopharmaceuticals Inc
Application granted granted Critical
Publication of ES2986461T3 publication Critical patent/ES2986461T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES18808978T 2017-05-30 2018-05-29 Método para producir un compuesto ópticamente activo Active ES2986461T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017106280 2017-05-30
PCT/IB2018/053822 WO2018220533A2 (ja) 2017-05-30 2018-05-29 光学活性化合物の製造法

Publications (1)

Publication Number Publication Date
ES2986461T3 true ES2986461T3 (es) 2024-11-11

Family

ID=64454503

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18808978T Active ES2986461T3 (es) 2017-05-30 2018-05-29 Método para producir un compuesto ópticamente activo

Country Status (12)

Country Link
US (2) US10988469B2 (enExample)
EP (2) EP3632441B1 (enExample)
JP (2) JP7102233B2 (enExample)
KR (1) KR102754527B1 (enExample)
CN (2) CN117447464A (enExample)
AU (1) AU2018276192B2 (enExample)
CA (1) CA3065683A1 (enExample)
EA (1) EA039880B1 (enExample)
ES (1) ES2986461T3 (enExample)
IL (1) IL270983B (enExample)
MX (1) MX391164B (enExample)
WO (1) WO2018220533A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102754527B1 (ko) 2017-05-30 2025-01-14 데이 원 바이오파마슈티칼즈, 인크. 광학 활성 화합물의 제조법
EP3950672A4 (en) * 2019-03-27 2023-01-11 Kyowa Pharma Chemical Co., Ltd. PROCESS FOR PRODUCTION OF PROSTAGLANDIN
AU2021376286A1 (en) * 2020-11-06 2023-06-22 Dana-Farber Cancer Institute, Inc. Raf inhibitor for treating low grade glioma
CN114685564B (zh) * 2020-12-27 2023-09-22 西北大学 新型亚磷酰胺配体及其合成方法和应用
CN117715889A (zh) 2021-07-26 2024-03-15 阿尔维纳斯运营股份有限公司 制备双官能化合物的方法
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法
CN119241530A (zh) * 2024-09-20 2025-01-03 武汉九州钰民医药科技有限公司 一种Tovorafenib的药物合成工艺
CN119241529A (zh) * 2024-09-20 2025-01-03 武汉九州钰民医药科技有限公司 一种Tovorafenib的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764842B2 (en) * 2001-03-28 2004-07-20 Merck & Co., Inc. Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
MY139887A (en) * 2004-04-02 2009-11-30 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same.
CA2694284A1 (en) * 2007-06-29 2009-01-08 Jennifer Cossrow Heterocyclic compounds useful as raf kinase inhibitors
TWI444379B (zh) 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Raf激酶抑制劑之化合物
EP3680240A1 (en) * 2012-03-14 2020-07-15 Merck Sharp & Dohme Corp. Asymmetric phase transfer catalysis
WO2013146987A1 (ja) 2012-03-28 2013-10-03 武田薬品工業株式会社 ロジウム触媒及びアミン化合物の製造法
TWI602803B (zh) * 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
WO2015178846A1 (en) * 2014-05-20 2015-11-26 Sp Process Development Ab Process for the preparation of chiral amines from prochiral ketones
JP6638363B2 (ja) 2015-12-11 2020-01-29 株式会社大林組 掘削装置および杭孔の拡径方法
CN105524111B (zh) * 2016-01-25 2017-10-27 西北农林科技大学 手性亚磷酰胺单齿配体及其合成方法与应用
KR102754527B1 (ko) 2017-05-30 2025-01-14 데이 원 바이오파마슈티칼즈, 인크. 광학 활성 화합물의 제조법

Also Published As

Publication number Publication date
US20200317659A1 (en) 2020-10-08
AU2018276192A1 (en) 2020-01-16
CN117447464A (zh) 2024-01-26
EP3632441C0 (en) 2024-07-17
EA039880B1 (ru) 2022-03-23
EA201992709A1 (ru) 2020-04-23
IL270983B (en) 2022-03-01
AU2018276192B2 (en) 2022-05-19
US10988469B2 (en) 2021-04-27
MX2019014256A (es) 2022-03-31
JP2022116043A (ja) 2022-08-09
JP2018203733A (ja) 2018-12-27
KR102754527B1 (ko) 2025-01-14
EP4406609A2 (en) 2024-07-31
US20210347769A1 (en) 2021-11-11
CN111032047A (zh) 2020-04-17
EP3632441A4 (en) 2021-01-13
JP7420865B2 (ja) 2024-01-23
KR20200013707A (ko) 2020-02-07
JP7102233B2 (ja) 2022-07-19
MX391164B (es) 2025-03-21
BR112019025355A2 (pt) 2020-06-23
WO2018220533A3 (ja) 2019-02-28
CA3065683A1 (en) 2018-12-06
WO2018220533A2 (ja) 2018-12-06
US12129249B2 (en) 2024-10-29
EP3632441A2 (en) 2020-04-08
CN111032047B (zh) 2023-10-27
EP4406609A3 (en) 2024-10-02
EP3632441B1 (en) 2024-07-17
IL270983A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
ES2986461T3 (es) Método para producir un compuesto ópticamente activo
US20180079741A1 (en) Process for producing heterocyclic compound
HK40114634A (en) Method for producing optically active compound
HK40022701B (en) Method for producing optically active compound
HK40022701A (en) Method for producing optically active compound
BR112019025355B1 (pt) Métodos para a produção de compostos oticamente ativos, composto e forma oticamente ativa
EP3590936B1 (en) Method for producing heterocyclic compound
US9878981B2 (en) Method for producing heterocyclic compound